FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 316:187-191 January 22, 1987 Number 4 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Since progesterone supports endometrial nidation of the fertilized ovum, a progesterone antagonist would theoretically block this process and thus have contraceptive potential. We have explored the ability of RU 486, a newly developed competitive progesterone antagonist, to function as a contraceptive agent. A single oral dose of 10 mg per kilogram of body weight given in the midluteal phase consistently induced menses within 72 hours in women with normal cycles and no risk of pregnancy. Bleeding was not prevented by administration of human chorionic gonadotropin in the midluteal phase. This suggested that giving a single dose of RU 486 late in the menstrual cycle might be an effective contraceptive strategy. This concept was tested in monkeys. When given to rhesus females on day 25 of the cycle, a single intramuscular dose of RU 486 (5 mg per kilogram) prevented pregnancy. The vehicle-treated control animals had a 28 percent pregnancy rate (P less than 0.05 by chi-square analysis). No side effects were noted in women or monkeys. These data suggest that a progesterone antagonist such as RU 486 has the potential to be an effective, safe, and convenient contraceptive agent. Further work will be necessary to assess the safety of long-term monthly administration and to define the optimal dose and time of administration in women.

This article has been cited by other articles:

• Stratton, P., Hartog, B., Hajizadeh, N., Piquion, J., Sutherland, D., Merino, M., Lee, Y. J., Nieman, L. K. (2000). A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 15: 1092-1099 [Abstract] [Full Text]  
• Spitz, I. M., Bardin, C.W. (1993). Mifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid Action. NEJM 329: 404-412 [Full Text]  
• Weiss, B. D. (1993). RU 486: The Progesterone Antagonist. Arch Fam Med 2: 63-69 [Abstract]  
• Baulieu, E. (1989). Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 245: 1351-1357 [Abstract]